Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- LYTIX.OL
- Price
- 5.02
- Stock movement up
- +0.14 (2.87%)
- Company name
- Lytix Biopharma AS
- Exchange
- (OL ,
- Currency
- NOK )
- Sector
- Healthcare >Biotechnology
- Market cap
- 249.04M
- Ent value
- 224.97M
- Price/Sales
- 23.15
- Price/Book
- 6.76
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- 6.68%
- 1 year return
- -21.81%
- 3 year return
- -22.54%
- 5 year return
- -
- 10 year return
- -
Last updated: 2025-04-09
DIVIDENDS
LYTIX.OL does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 23.15 |
| Price to Book | 6.76 |
| EV to Sales | 20.91 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 49.61M |
| EPS (TTM) | -1.63 |
| FCF per share (TTM) | -1.64 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 10.76M |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -82.78M |
| Net income (TTM) | -80.90M |
| EPS (TTM) | -1.63 |
| EPS (1y forward) | - |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -769.59% |
| Profit margin (TTM) | -752.03% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 43.53M |
| Net receivables | 9.90M |
| Total current assets | 53.43M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 2.85M |
| Total assets | 56.28M |
| Accounts payable | 2.44M |
| Short/Current long term debt | 0.00 |
| Total current liabilities | 17.38M |
| Total liabilities | 19.45M |
| Shareholder's equity | 36.83M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -81.21M |
| Capital expenditures (TTM) | 0.00 |
| Free cash flow (TTM) | -81.21M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -219.65% |
| Return on Assets | -143.73% |
| Return on Invested Capital | -219.65% |
| Cash Return on Invested Capital | -220.50% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 4.74 |
| Daily high | 5.18 |
| Daily low | 4.74 |
| Daily Volume | 38K |
| All-time high | 17.39 |
| 1y analyst estimate | 14.00 |
| Beta | -0.68 |
| EPS (TTM) | -1.63 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | - |
Downside potential
Loading...
Downside potential data
| LYTIX.OL | S&P500 | |
| Current price drop from All-time high | -71.13% | -19.00% |
| Highest price drop | -73.08% | -56.47% |
| Date of highest drop | 4 Jan 2024 | 9 Mar 2009 |
| Avg drop from high | -49.52% | -11.07% |
| Avg time to new high | 483 days | 12 days |
| Max time to new high | 964 days | 1805 days |
COMPANY DETAILS
Marketcap
249.04M
Marketcap category
Small-cap
Description
Lytix Biopharma ASA, a clinical stage biotech company, develops novel cancer immunotherapies for cancer therapy in Norway. Its lead product candidate is LTX-315, an oncolytic molecule that is developed for intratumoral injections, is designed for the local treatment of solid tumors that is in Phase II clinical trials. The company's products comprise of LTX-401, an oncolytic molecule for targeting deep-seated lesions, such as liver cancer and is in a preclinical phase. Lytix Biopharma ASA was incorporated in 2003 and is based in Oslo, Norway.
Employees
0
Investor relations
-
SEC filings
CEO
Country
Norway
City
Stock type
-
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
No items found